AOD-9604 Dosage Chart
Daily subcutaneous protocol, fasted-morning timing, and reconstitution math — with clear limits on the cited mouse evidence.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
AOD-9604 is a fragment of the C-terminus of human growth hormone (residues 177–191), originally developed as an anti-obesity agent. The cited paper is an obese-mouse and beta(3)-adrenergic-receptor knockout study; it does not establish human dosing or efficacy. Compounded use at 250–500 mcg daily is off-label clinic/vendor practice, and human efficacy data is weak.
AOD-9604 at a Glance
| Typical dose | 250–500 mcg subQ daily (clinic/vendor convention) |
|---|---|
| Best timing | AM fasted, before breakfast (clinic/vendor convention) |
| Cycle length | 12 weeks on, 4 weeks off (clinic/vendor convention) |
| FDA status | Not FDA-approved. No cited FDA label or human efficacy source. |
| Source quality | Cited source is obese-mouse and beta(3)-AR knockout work; human efficacy data is weak. |
| Common vial size | 5 mg lyophilized powder |
AOD-9604 Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for AOD-9604. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL (250 mcg per 0.1 mL) |
|
| 5 mg | 2.5 mL | 2 mg/mL (200 mcg per 0.1 mL) |
|
AOD-9604 Dosing by Use Case
Commonly cited protocols vary by what AOD-9604 is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Adjunctive fat loss | 250–500 mcg | Once daily, AM fasted | 12 weeks | Often paired with caloric deficit and exercise in clinics; human efficacy is not established by the cited mouse work. |
Stacking AOD-9604
AOD-9604 is occasionally stacked with semaglutide or tirzepatide as an adjunctive 'metabolic support' add-on, but the evidence base for adding AOD-9604 to a GLP-1 protocol is essentially non-existent. The cited mouse work does not establish additive human benefit.
Where these numbers come from
The cited PubMed paper tested hGH and AOD9604 in obese mice and beta(3)-adrenergic-receptor knockout mice; it is not a human dosing or efficacy trial. Published human efficacy data for AOD-9604 is weak, and this chart does not cite a human trial establishing weight-loss benefit. The 250-500 mcg daily subQ, fasted-morning, 12-week protocol is clinic/vendor convention, not a dose derived from the cited mouse paper or an FDA label.
AOD-9604 has weak human efficacy support, and the cited source does not establish human safety or a human weight-loss protocol.
- •The cited mouse study does not establish human safety, weight-loss efficacy, or a 12-week injected protocol.
- •Human efficacy data is weak; set expectations accordingly.
- •Not FDA-approved.
- •Theoretical concern: as an HGH fragment, long-term effects on insulin sensitivity and metabolic homeostasis are not well characterized.
- •Pregnancy or breastfeeding
- •Active malignancy (theoretical concern, class-effect for GH-related peptides)
AOD-9604 Dosing FAQ
The cited paper is in mice, not humans. Human efficacy data for AOD-9604 is weak, and practitioner-reported anecdotal results vary. If you're looking for evidence-backed weight loss, FDA-approved options like semaglutide or tirzepatide have substantially stronger data.
Some practitioners use it as a metabolic adjunct on the theory that it may work synergistically with caloric restriction. The honest framing is that the formal human efficacy evidence is weak and the cited source is preclinical.
Sources
Related Dosage Charts
Where to get AOD-9604 with a prescription
AOD-9604 requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Want the full AOD-9604 guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for AOD-9604 therapy.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.